Clinical Trial: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL628 in Participants With Early Alzheimer's Disease

U.S., Jan. 10 -- ClinicalTrials.gov registry received information related to the study (NCT07328451) titled 'A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL628 in Participants With Early Alzheimer's Disease' on Dec. 24, 2025.

Brief Summary: This is a Phase 1b, multicenter, randomized, placebo-controlled, double-blind, multiple asecending dose (MAD) study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of DNL628 in participants with early Alzheimer's disease (AD), defined as mild cognitive impairment, or mild AD with biomarker evidence of amyloid positivity.

Study Start Date: Jan., 2026

Study Type: INTERVENTIONAL

Condition: Alzheimer Disease, Early Onset...